ANG1005 in Leptomeningeal Disease From Breast Cancer

PHASE3UnknownINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Leptomeningeal CarcinomatosisLeptomeningeal MetastasesBrain MetastasesHER2-negative Breast Cancer

Interventions

DRUG

ANG1005

Investigational drug

DRUG

Physician's Best Choice

Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.